Frankfurt Am Main

• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade … Ended
  2023-504328-25-00 4 2023-12-27 hidradenitis suppurativa
• Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended
  2022-503160-33-00 5 2023-12-15 Hidradenitis Suppurativa
• A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release … Ended
  2023-505296-72-00 4 2023-12-12 Idiopathic Pulmonary Fibrosis (IPF)
• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 5 2023-12-11 ulcerative pyoderma gangrenosum
• A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and … Ended
  2023-503577-38-00 1 2023-12-07 Atopic Dermatitis
• A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18 … Ended
  2024-510571-37-00 7 2023-12-06 Herpes Simplex
• Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease. Ended
  2024-512648-45-00 5 2023-11-30 Thyroid Eye Disease (TED)
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C … Ended
  2022-502840-11-00 9 2023-11-28 Hepatocellular Carcinoma (Morpheus-Neo HCC)
• A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized … Ended
  2023-504487-41-00 5 2023-11-28 COVID-19
• A study to test whether BI 765845 helps people who have had a heart attack Ended
  2022-502788-39-00 4 2023-11-27 acute myocardial infarction
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 4 2023-11-25 Asthma
• Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended
  2022-503062-72-00 4 2023-11-23 Chronic Spontaneous Urticaria
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (PRESent-3) Ended
  2022-502881-25-00 4 2023-11-16 Hemophilia B
• A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended
  2022-502370-17-00 4 2023-11-14 Hidradenitis suppurativa
• A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moder … Ended
  2022-502880-39-00 4 2023-11-13 Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
• Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin Ended
  2023-503696-15-00 4 2023-11-10 sensorineural hearing loss (SNHL)
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended
  2022-500897-32-00 5 2023-11-02 Chronic pain due to diabetic polyneuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended
  2022-500898-13-00 5 2023-11-02 Chronic Pain due to traumatic or post-operative peripheral Neuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended
  2022-500899-66-00 5 2023-11-02 Chronic pain due to central Neuropathy of any Genesis
• Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended
  2022-502151-54-00 5 2023-11-02 Chronic back pain
• A Study to Investigate MBS2320 Patients with IPF Ended
  2023-504418-30-00 4 2023-10-24 Idiopathic Pulmonary Fibrosis

Showing 745–768 of 912 trials